SCHADE CHRISTIAN S
SCHADE CHRISTIAN S's purchase track record
SCHADE CHRISTIAN S has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/18/2022 | APRE | $24K | +37.8% | -36.8% | +0.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Aprea Therapeutics Announces October Conference Presentations. Aprea Therapeutics will present at several conferences in October. The company’s appearance is intended to share progress on its research and development efforts. The presentation may offer new information to investors and analysts about the company’s pipeline and strategy. The event is a routine update for the company’s stakeholders.
Transaction History
| IART | ▲ Buy | Grant | 6,939 | $0 | 5/9/2025 | View on chart |
| IART | ▲ Buy | Grant | 19,592 | $0 | 5/9/2025 | View on chart |
| IART | ▲ Buy | Grant | 8,696 | $0 | 5/9/2024 | View on chart |
| IART | ▲ Buy | Grant | 4,486 | $0 | 5/12/2023 | View on chart |
| APRE | ▲ Buy | Grant | 32,400 | $0 | 7/28/2022 | View on chart |
| APRE | ▼ Sell | Tax Withholding | 65,770 | $53K | 6/3/2022 | View on chart |
| APRE | ▲ Buy | Open Market | 37,500 | $24K | 5/18/2022 | View on chart |
| IART | ▲ Buy | Grant | 1,265 | $0 | 5/13/2022 | View on chart |
| IART | ▲ Buy | Grant | 3,456 | $0 | 5/13/2022 | View on chart |
| APRE | ▲ Buy | Grant | 100,100 | $0 | 3/10/2022 | View on chart |
| APRE | ▼ Sell | Tax Withholding | 21,644 | $38K | 2/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
IART May Be 48% Undervalued Based on Cash Flow Analysis
A recent Yahoo analysis suggests Integra LifeSciences shares could be trading about 48% below their intrinsic value when cash flow is considered. The stock sits near its 13‑touch support level of $9.10 and an RSI of 41.6, indicating neither overbought nor oversold conditions. The average analyst target is $19.56, well above the current price, highlighting a potential valuation gap. This analysis may prompt a closer look at the company’s cash flow performance relative to market expectations.
IART May Be 48% Undervalued Based on Cash Flow Analysis. A recent Yahoo analysis suggests Integra LifeSciences shares could be trading about 48% below their intrinsic value when cash flow is considered. The stock sits near its 13‑touch support level of $9.10 and an RSI of 41.6, indicating neither overbought nor oversold conditions. The average analyst target is $19.56, well above the current price, highlighting a potential valuation gap. This analysis may prompt a closer look at the company’s cash flow performance relative to market expectations.